NEW YORK (GenomeWeb) – BGI and Clearbridge BioMedics said today that they have signed a partnership agreement, under which they will solely distribute and market Clearbridge's ClearCell FX1 solution and related liquid biopsy products in China.

BGI said that it also hopes to use its genomics expertise and capabilities to extend Clearbridge's ClearCell FX1 circulating tumor cell system into new clinical research applications, as well as develop specific clinical products using the platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.